Search results
Bisphosphonates are the most widely used anti-resorptives, reducing bone turnover markers to low premenopausal concentrations and reducing fracture rates (vertebral by 50–70%, non-vertebral by 20–30%, and hip by ~40%). Bisphosphonates bind avidly to bone mineral and have an ofset of efect measured in months to years.
28 kwi 2022 · Current FDA-approved pharmacologic therapeutics for prevention and/or treatment of postmenopausal osteoporosis include bisphosphonates (alendronate, alendronate plus D, ibandronate, risedronate, and zoledronic acid), estrogens (estrogen and/or hormone therapy), estrogen agonist/antagonist (raloxifene), tissue-selective estrogen complex ...
7 lis 2017 · Because of the roles estrogen receptor α and estrogen receptor β play in osteoclast apoptosis, the use of estrogen replacement therapy or estrogenprogestin (hormone) replacement therapy with tibolone is effective for prevention of osteoporosis in post-menopausal women.
15 sie 2014 · This Guide offers concise recommendations regarding prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older. It includes indications for bone densitometry and fracture risk thresholds for intervention with pharmacologic agents.
Two types of calcitonin are used in therapy: Human and salmon calcitonin. Salmon calcitonin is used more often due to its high affinity for human calcitonin receptors. Calcitonin treatment is usually considered a second-line therapy for osteoporosis, and it is used when first-line therapy is ineffective or intolerable (78,101,113).
26 mar 2020 · Pharmacotherapy of osteoporosis is the main treatment option for these patients because of strong evidence about the efficacy of available drugs targeting bone metabolism.
17 wrz 2024 · Tiliroside may be used for treating the osteoporosis by decreasing the activation and expression of signaling proteins regulated by RANKL, as well as by reducing the generation of ROS in cells involved in osteoclast formation.
